The state squeezed the price of medicines and then squeezed the "moisture" of these commonly used medicines to cut the "floor price"

3rd, the fourth batch of high-profile national drug collection announced the results of the proposed winning drug, the average price reduction of the drug to be selected 52%. It is worth noting that in this round of collection, the variety of injections increased significantly, as well as drugs for the treatment of mental illness also included.In the eyes of industry experts, the future of domestic high-end generic drug replacement of the original research drug market process will accelerate, at the same time, domestic pharmaceutical companies are also facing more intense competition for innovative technology, as well as industry reshuffle integration.

the price of collecting drugs and then "diving" antidepressants into theThe proposed drug price of the large "diving" is still the highlight of this collection of the most attention. All 45 drugs included in the procurement were successfully procured, with an average price reduction of 52 per cent.This batch of collection, a lot of anti-cancer drug prices directly "waist cut".For example, the price of the anti-cancer drug soraphinist dropped from 95 yuan to 30 yuan, according to the daily consumption of 2 tablets, can save patients 3900 yuan per month. The price of the anti-cancer drug boratezomi injection for the treatment of multiple myeloma was reduced from 1500 yuan to 600 yuan, saving about 36,000 yuan for the entire course of treatment.In addition, the stomach ulcer treatment drug Esomeprazole intestinal tablets (20mg / tablet), after the collection of each piece price from 9 yuan to 3 yuan, the entire course of treatment can save about 240 yuan.It is worth mentioning that this collection for the first time included a number of injection varieties, including 8 injection varieties, more than the sum of the first three batches, the collection coverage drug dosage form category further expanded. Eight varieties accounted for 31% of the total amount of medicines purchased, with an average price reduction of 75%.Taking the clinically widely used ammonia hydrochloride bromosot injection as an example, yunnan Longhai Natural Plant Pharmaceutical Co., Ltd. products are only 2.3 yuan, the average price is only more than 2 mao.Injections are widely used in clinical practice, the dosage is large, and the inclusion of multiple injectable products in the collection can be reduced, which means that the national collection is further expanding coverage.In addition, the procurement of drugs related to hypertension, diabetes, digestive diseases, malignant tumors and other therapeutic areas, but also related to psychotic drugs, including antidepressants.For example, for the treatment of depression and widespread anxiety disorders of hydrochloric acid Lositin intestinal capsules, this collection has a number of domestic pharmaceutical companies into the procurement of generic products, including Qingdao Baiyang Pharmaceutical Co., Ltd., Shanghai Sinopharm Sino-Western Pharmaceutical Co., Ltd., Shi Pharmaceutical Group Ohi Pharmaceutical Co., Ltd.

more innovative than the price of accelerated replacement of originalAccording to information from the State Health Insurance Administration, a total of 152 enterprises participated in the collection, resulting in 118 enterprises to be selected, and the proportion of enterprises to be selected increased to 71%.It is worth noting that in this collection, some multinational pharmaceutical companies have also changed the "Buddhist" attitude, positive quotations.The 158 products to be selected include 5 products from 5 foreign-funded enterprises, involving multinational pharmaceutical companies in Germany, France, India and Japan.For example, Fessenyuscabi's propofol medium/long-chain fat emulsions and Sanofi's ammonia pills have both been reduced by more than 80 per cent, outscaleing local pharmaceutical companies.On the other hand, with the landing of multiple rounds of collection, the competitive pattern of generic drugs accelerated to replace the original research drugs has become more and more prominent.Of the 158 products to be selected, 156 were generics evaluated for consistency of quality and efficacy, and 2 were originally developed. Generics account for an absolute proportion.Industry analysis, the collection of some varieties of the main market share occupied by the original research drugs, domestic pharmaceutical companies can quickly seize market share with the help of generic drugs.At the same time, along with the continuous promotion of consistent evaluation, collecting will become a generic sales model, and with the reduction of product prices, drug access is further improved, the speed of product release greatly increased.In the context of increasingly fierce competition in domestic generic drugs, in addition to price, technological innovation is also the key focus of the survival of the fittest competition.For example, Baiyang Pharmaceutical General Manager Zheng Aiju on the media introduction, the enterprise in this selected collection of hydrochloric acid Loxitin intestinal capsules using intestinally soluble micro-pill wrapping process (including the pharmaceutical layer, isolation layer, intestinal solution layer), the production process is complex, the drug preparation technology has a very big challenge, high-end generic technology competition.

countries to "squeeze water" should be picked into the inevitable trend“ Group purchase, soul cut price, the state shot to squeeze water... Public opinion often describes the concentration of drug procurement.Indeed, from the "4 plus 7" collection pilot to the national expansion, the two years of national "group purchase" drugs brought breakthrough results: three batches of national collection of a total of 112 drugs, an average price reduction of 54%, saving costs overall more than 100 billion yuan.Prior to the results of the selection, the General Office of the State Council had just issued the Opinions on Promoting the Normal Institutionalization of the Purchase of Drug Concentrated Bands.Among them, it is clearly put forward, in accordance with the principle of basic protection, clinical protection, focusing on the basic medical insurance drug catalog of large quantities of drugs, high procurement amount of drugs into the procurement scope, and gradually cover the domestic market clinically necessary, reliable quality of all kinds of drugs, so that should be harvested.In addition, the paper emphasizes that priority is given to the procurement of medicines that are evaluated for consistency in the quality and efficacy of generic drugs (including the same as between) and the following. Eligible drugs reach a certain amount or amount, that is, to initiate centralized strip procurement. We will actively explore suitable procurement methods for "orphan drugs" and shortages of medicines to promote supply stability.This means that in the future, the inclusion of more types of medicines and therapeutic drugs in national drug collection is a foreche, and the public's "drug price list" options will continue to expand.And for pharmaceutical companies, especially for domestic generic drug companies, collection is more like an industry reshuffle watershed.Fu Gang, vice president of the China Pharmaceutical Business Association, to the media analysis, if it is generic drugs, the original no certain market size, the enterprise itself has no international layout, domestic collection and no winning bid, in the hospital there is no such opportunity to be prescribed by the first patient, enterprise development will be more difficult.“ Thousands of pharmaceutical companies this decentralized pattern, the entire industry is also immature performance, there will be an integration process. "Fugang analysis, domestic generic drug companies will experience a "merger of similar items", some powerful enterprises to win, the industry gradually matured, which is beneficial to market supervision and industrial ecology. (China News Network)